Most evaluable patients who had not progressed ( > 74 % ) completed all HRQoL assessments for at least 1 year of treatment , and almost all completed at least one HRQoL assessment at baseline ( 98.3 % and 97.6 % , bevacizumab and placebo arms , respectively ) .